Please login to the form below

Not currently logged in
Email:
Password:

Icon to set up translational medicine centre in the UK

Expands early phase research presence at new Manchester site

Contract research organisation Icon is expanding its early phase research presence in the UK and setting up a new translational medicine centre.

Based in the Citylabs biomedical centre on the former site of the Manchester Royal Eye Hospital, Icon's Centre of Excellence for Translational Medicine will occupy a 40,000 sq ft site and is due to open before the end of 2013.

At this time Icon will also move the phase I operations of its hospital-based clinical pharmacology unit to Citylabs from its current base on the Manchester Royal Infirmary Campus.

President of Icon Development Solutions Dr Mario Rocci said: “We are pleased to be expanding our early phase development services through the establishment of a Centre of Excellence for Translational Medicine in Citylabs.

“This expansion will enable Icon to increase the capacity of its Clinical Pharmacology Unit in Manchester as well as the scientific services that are essential in providing a world class offering.”

Translational research is a way of conducting scientific research 'from bench to bedside' and also 'from bedside to bench', to ensure the results will be applicable to the relevant patient population 

Along with Icon's Translational Medicine Research Centre, Citylabs be home to a number of other health organisations, including the Central Manchester University Hospitals NHS Foundation Trust, The University of Manchester and commercial research organisations.

Mike Deegan, chief executive of Central Manchester University Hospitals NHS Foundation Trust, said: “This exciting development supports our progress to be the leading hospital for research and patient care in England and Citylabs will strengthen our capability to support the development of new medicines and diagnostics for our patients.

“We are pleased that Icon, who is one of the leaders in early phase trials, is expanding into Citylabs which will help our patients to get early access to leading edge new treatments.”

8th August 2012

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics